Synopsis A clinical study demonstrates that Osteoprotegerin ( OPG) increases in obese adolescents in comparison with their lean counterparts, especially if Insulin Resistance ( IR) is present. This could be a harbinger of worse glucose metabolism, increased risk of atherosclerosis, and finally complications such as T2DM and cardiovascular disease. This week's 'MED FACT' discusses a clinical trial from Endocrine research , “ Osteoprotegerin increases parallel to insulin resistance in obese adolescents ”. June, 2018.
Authors : Kotanidou EP, Kotanidis CP, Giza S, Serbis A, et.al. Key Takeaways Insulin Resistance accompanying obesity exerts a fundamental role in Osteoprotegerin upregulation. Objective Study Type Participants To study the relation of OPG level with obesity-related insulin resistance Systematic clinical examination 160 What Was The Need For This Study?…
